Skip to main content
. 2019 Nov 20;20(23):5819. doi: 10.3390/ijms20235819

Table 4.

Antibody-modified nanoparticles.

Name Ligand Carrier Therapeutics Cancer Type Ref
liposomal sodium morrhuate IgG against VEGFR2 LP sodium morrhuate hemangioma [67]
PLD Fab’ against VEGFR2 LP DOX pancreatic cancer [69]
CMB105 IgG against CD105 microbubble LP pDNA encoding endostatin breast cancer [70,73]
ICAM-Lcn2-LP IgG against ICAM-1 LP siRNA against lipocalin 2 breast cancer [74]
ENG-scFv-iLPs scFv against endoglin LP pDNA encoding porcine α1,3 galactosyltransferase lung cancer [78]